Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10-strain probiotic combination (Fuwai Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This investigational probiotic combination is a live biotherapeutic product containing 10 distinct strains from the *Lactobacillus* and *Bifidobacterium* genera. Developed by the Chinese Academy of Medical Sciences, Fuwai Hospital, it is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled pilot trial (NCT05095350) for the treatment of grade 1 primary hypertension and prehypertension. The therapy is based on the hypothesis that gut microbiota dysbiosis contributes to the pathogenesis of high blood pressure; previous metagenomic analyses by the investigators indicated a deficiency of specific probiotics in hypertensive patients. By restoring these microbial populations, the intervention aims to modulate the gut-brain or gut-vascular axis to achieve blood pressure reduction.
- Other names
- Probiotic powderLactobacillus and Bifidobacterium probiotic combination
Beyond the preview
Go deeper on 10-strain probiotic combination (Fuwai Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 10-strain probiotic combination (Fuwai Hospital).